RxDoctor Payments Data

Florence Awosika

Family · Greenbelt, MDNPI 1922381987

Payments from drug & device makers

$4,639in general payments, 2019–2025

Across 52 payments — averaging $89.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Lilly USA, LLC$335
  • Neurocrine Biosciences, Inc.$231
  • Tandem Diabetes Care, Inc.$228
  • BETA Bionics, Inc.$220
  • Sanofi-aventis U.S. LLC$202
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$1,19026%
  • Food & beverage$3,44974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,639 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$16,673
Medicare patients
32
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$22,250
JardianceEmpagliflozin12$16,564
MounjaroTirzepatide13$14,160
EntrestoSacubitril/Valsartan15$10,363
SantylCollagenase Clostridium Hist.15$9,775
BrilintaTicagrelor11$4,767
Humalog Kwikpen U-100Insulin Lispro25$3,860
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$2,936
Comfort Ez Pen NeedlePen Needle, Diabetic29$2,640
Memantine Hcl ErMemantine Hcl14$1,473
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,397
Pro Comfort Alcohol PadsAlcohol Antiseptic Pads14$705
Pregabalin12$657
Gabapentin26$374
Duloxetine Hcl17$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$335$14,16013 claims
AstraZenecaBrilinta$116$4,76711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →